Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) Shares Shorted: Short Interest Down 50.2% in September

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 947,657 shares, a decrease of 50.2% from the September 15th total of 1,904,283 shares. Based on an average daily volume of 26,546,756 shares, the days-to-cover ratio is currently 0.0 days. Approximately 11.7% of the company’s shares are sold short.

Mymd Pharmaceuticals Price Performance

Shares of QCLS stock traded down $0.02 on Friday, hitting $0.54. The stock had a trading volume of 123,030 shares, compared to its average volume of 2,104,449. The firm has a 50 day moving average of $1.53. Mymd Pharmaceuticals has a 1 year low of $0.42 and a 1 year high of $8.17. The firm has a market capitalization of $4.41 million, a price-to-earnings ratio of -0.15 and a beta of 2.32.

Mymd Pharmaceuticals (NASDAQ:QCLS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.79) EPS for the quarter.

Wall Street Analyst Weigh In

QCLS has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a report on Friday, August 7th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases, inflammation and age-related conditions. The company has historically pursued treatments designed to regulate the immune system and address biological processes associated with chronic disease and aging.

MyMD’s principal investigational product has been MYMD-1, an orally administered small-molecule therapy intended to modulate immune and inflammatory responses.